Literature DB >> 1387464

Serotonergic dysfunction in depression associated with Parkinson's disease.

E F McCance-Katz1, K L Marek, L H Price.   

Abstract

A 55-year-old man presented with a 5-year history of Parkinson's disease and a 6-month history of major depression. The patient's depressive symptoms responded to treatment with fluvoxamine, a selective and potent serotonin reuptake inhibitor. Tryptophan depletion testing, which acutely lowers central serotonin levels, caused a brief exacerbation of the depressive illness, which resolved upon tryptophan repletion. Serotonergic dysfunction may be an etiologic factor in depression that occurs in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387464     DOI: 10.1212/wnl.42.9.1813

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Depression in Parkinson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 2.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 4.  Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data.

Authors:  B Scholtissen; F R J Verhey; H W M Steinbusch; A F G Leentjens
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

Review 5.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

6.  Simultaneous [99mTc]TRODAT-1 and [123I]ADAM brain SPECT in nonhuman primates.

Authors:  Kuo-Hsing Ma; Jong-Kang Lee; San-Yuan Huang; Chin-Bin Yeh; Yi-Chun Shen; Lie-Hang Shen; Chia-Chieh Chen; Ren-Shyan Liu; Jiang-Chuan Liu; Wen-Sheng Huang
Journal:  Mol Imaging Biol       Date:  2009-02-19       Impact factor: 3.488

7.  Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus.

Authors:  Yasin Temel; Laura J Boothman; Arjan Blokland; Peter J Magill; Harry W M Steinbusch; Veerle Visser-Vandewalle; Trevor Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

Review 8.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972

9.  Serotonergic mechanisms of cocaine effects in humans.

Authors:  S C Aronson; J E Black; C J McDougle; B E Scanley; P Jatlow; T R Kosten; G R Heninger; L H Price
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

10.  Non-motor off symptoms in Parkinson's disease.

Authors:  Sang-Myung Cheon; Min Jeong Park; Wook-Joo Kim; Jae Woo Kim
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.